NCT00874549View on ClinicalTrials.gov

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

October 31, 2008

Conditions
Meningococcal InfectionsMeningococcal Meningitis
Interventions
BIOLOGICAL

Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide

0.5 mL, Subcutaneous

BIOLOGICAL

Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

BIOLOGICAL

Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL. Intramuscular

BIOLOGICAL

Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

Trial Locations (6)

40004

Bardstown

84088

West Jordon

85251

Scottsdale

87108

Albuquerque

98101

Seattle

99202

Spokane

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00874549 - Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years | Biotech Hunter | Biotech Hunter